{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:02:59Z","timestamp":1792735379046,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The US Preventive Services Task Force (USPSTF) recommends annual computed tomographic (CT) screening for individuals aged 50 to 80 years at high risk of lung cancer. Other countries are issuing similar recommendations, with some opting for biennial screening to reduce the burden of screening. However, it is unknown whether benefits of annual screening can be preserved when adapting the interval to age, sex, and smoking history.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the health outcomes and costs of adaptive lung cancer screening intervals relative to annual screening.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This economic evaluation used comparative modeling methods with 3 models: 2 Cancer Intervention and Surveillance Modeling Network models and the OncoSim model from the Canadian Partnership Against Cancer. Screening of the US 1965 birth cohort with adaptive intervals was evaluated according to age, sex, and smoking exposure. Simulated outcomes are recorded from 2005 to 2065 for subpopulations of 200\u202f000 individuals with smoking history of 10 to less than 20, 20 to less than 30, and 30 or greater pack-years (PY) for each sex. This evaluation was conducted between September 19, 2023, to December 1, 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Low-dose regular CT screening among those eligible per USPSTF 2021 recommendations.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Strategy effectiveness was evaluated as lung cancer deaths prevented and life-years gained relative to annual screening. Screening burden is measured by the number of CT screens. To determine cost-effectiveness, quality-adjusted life-years (QALYs) gained and Surveillance, Epidemiology, and End Results\u2013 and Medicare-derived costs of treatment were calculated, as well as CT and follow-up examination costs. A willingness-to-pay (WTP) threshold of $100 000\/QALY for cost-effectiveness was assumed.<\/jats:p><\/jats:sec>Results<\/jats:title>Biennial screening at 50 to 60 years of age, followed by annual screening, reduced CT requirements while preserving most benefits. This strategy preserved 95.9% (intermodel range, 93.5%-97.5%) of lung cancer deaths prevented, compared with annual screening, with 20.6% (intermodel range, 19.3%-21.9%) fewer screens. Annual screening from 50 to 80 years of age was not cost-effective at a WTP threshold of $100 000\/QALY. Cost-effective strategies varied by risk group, but all cost-effective strategies started with biennial screening and moved to annual screening at 60 years of age or a PY threshold of 30 to 40 was reached.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this economic evaluation of lung cancer screening, biennial screening for participants younger than 60 years and those with less than 30 PY of smoking exposure maintained screening benefits relative to annual screening. Resource-constricted screening programs may consider adaptive intervals.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.23044","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:31:09Z","timestamp":1753371069000},"page":"e2523044","source":"Crossref","is-referenced-by-count":6,"title":["Computed Tomographic Screening Intervals for Patients at Moderate Risk of Lung Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Koen","family":"de Nijs","sequence":"first","affiliation":[{"name":"Department of Public Health, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J.","family":"de Koning","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pianpian","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Health and Human Sciences, Purdue University, West Lafayette, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikol","family":"Diasparra","sequence":"additional","affiliation":[{"name":"Statistics Canada, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Garner","sequence":"additional","affiliation":[{"name":"Statistics Canada, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyoun","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean H. E.","family":"Yong","sequence":"additional","affiliation":[{"name":"Canadian Partnership Against Cancer, Toronto, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Meza","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute, Vancouver, British Columbia, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"ten Haaf","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"5","key":"zoi250670r1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening.","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi250670r2","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"zoi250670r3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial.","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250670r4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","article-title":"Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.","volume":"18","author":"Oudkerk","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"zoi250670r5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US.","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"zoi250670r6","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1001\/jama.2021.1077","article-title":"Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force.","volume":"325","author":"Meza","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"zoi250670r7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.chest.2019.08.2176","article-title":"Lung cancer screening uptake in the United States.","volume":"157","author":"Yong","year":"2020","journal-title":"Chest"},{"issue":"1","key":"zoi250670r8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacr.2022.11.005","article-title":"Repeat annual lung cancer screening after baseline screening among screen-negative individuals: no-cost coverage is not enough.","volume":"20","author":"Tailor","year":"2023","journal-title":"J Am Coll Radiol"},{"issue":"3","key":"zoi250670r9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.chest.2021.09.002","article-title":"Guideline-recommended lung cancer screening adherence is superior with a centralized approach.","volume":"161","author":"Smith","year":"2022","journal-title":"Chest"},{"issue":"6","key":"zoi250670r10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ypmed.2012.10.007","article-title":"How to increase uptake in oncologic screening: a systematic review of studies comparing population-based screening programs and spontaneous access.","volume":"55","author":"Ferroni","year":"2012","journal-title":"Prev Med"},{"issue":"5","key":"zoi250670r11","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000577","article-title":"Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion.","volume":"4","author":"Field","year":"2019","journal-title":"ESMO Open"},{"issue":"5","key":"zoi250670r12","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.21037\/tlcr-20-890","article-title":"Lung cancer screening in Europe: where are we in 2021?","volume":"10","author":"van Meerbeeck","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"zoi250670r14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/ijc.34746","article-title":"Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.","volume":"154","author":"Tomonaga","year":"2024","journal-title":"Int J Cancer"},{"issue":"3","key":"zoi250670r15","first-page":"84","article-title":"BC cancer lung screening program: insights on a risk model-based approach for primary care providers.","volume":"65","author":"Lam","year":"2023","journal-title":"BCMJ"},{"issue":"6","key":"zoi250670r16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s41669-022-00346-2","article-title":"Cost-effectiveness analyses of lung cancer screening using low-dose computed tomography: a systematic review assessing strategy comparison and risk stratification.","volume":"6","author":"Fabbro","year":"2022","journal-title":"Pharmacoecon Open"},{"issue":"4","key":"zoi250670r17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/0272989X211050918","article-title":"Risk stratification in cost-effectiveness analyses of cancer screening: intervention eligibility, strategy choice, and optimality.","volume":"42","author":"O\u2019Mahony","year":"2022","journal-title":"Med Decis Making"},{"key":"zoi250670r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102743","article-title":"Benchmarking lung cancer screening programmes with adaptive screening frequency against the optimal screening schedules derived from the ENGAGE framework: a comparative microsimulation study.","volume":"74","author":"Hemmati","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"zoi250670r19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/09691413221118194","article-title":"Evaluation of benefits and harms of adaptive screening schedules for lung cancer: A microsimulation study.","volume":"29","author":"Cao","year":"2022","journal-title":"J Med Screen"},{"issue":"3","key":"zoi250670r20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7326\/M22-2216","article-title":"Risk model-based lung cancer screening: a cost-effectiveness analysis.","volume":"176","author":"Toumazis","year":"2023","journal-title":"Ann Intern Med"},{"key":"zoi250670r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102570","article-title":"Projected effectiveness of lung cancer screening and concurrent smoking cessation support in the Netherlands.","volume":"71","author":"de Nijs","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"zoi250670r22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/cncr.34925","article-title":"Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: a simulation modeling study.","volume":"130","author":"Meza","year":"2024","journal-title":"Cancer"},{"key":"zoi250670r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101241","article-title":"Targeted lung cancer screening in the age of immunotherapies and targeted therapies - an economic evaluation for Australia.","volume":"53","author":"Roseleur","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"11","key":"zoi250670r24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/cncr.28623","article-title":"Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.","volume":"120","author":"Meza","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"zoi250670r25","doi-asserted-by":"publisher","first-page":"E585","DOI":"10.9778\/cmajo.20190134","article-title":"Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.","volume":"8","author":"Evans","year":"2020","journal-title":"CMAJ Open"},{"issue":"5","key":"zoi250670r26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/0272989X241249182","article-title":"The impact of model assumptions on personalized lung cancer screening recommendations.","volume":"44","author":"Ten Haaf","year":"2024","journal-title":"Med Decis Making"},{"issue":"2","key":"zoi250670r27","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.amepre.2013.10.022","article-title":"Patterns of birth cohort-specific smoking histories, 1965-2009.","volume":"46","author":"Holford","year":"2014","journal-title":"Am J Prev Med"},{"issue":"11","key":"zoi250670r28","first-page":"16","article-title":"Smoking patterns based on birth-cohort-specific histories from 1965 to 2013, with projections to 2041.","volume":"31","author":"Manuel","year":"2020","journal-title":"Health Rep"},{"issue":"1","key":"zoi250670r29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3322\/caac.21811","article-title":"Screening for lung cancer: 2023 guideline update from the American Cancer Society.","volume":"74","author":"Wolf","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"zoi250670r30","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1001\/jamaoncol.2021.4942","article-title":"Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force recommendation for lung cancer screening.","volume":"7","author":"Toumazis","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi250670r31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/cam4.1896","article-title":"Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare.","volume":"8","author":"Sheehan","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"zoi250670r32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0272989X15570364","article-title":"Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.","volume":"35","author":"Tramontano","year":"2015","journal-title":"Med Decis Making"},{"issue":"10","key":"zoi250670r34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"zoi250670r35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jval.2023.04.005","article-title":"Designing guidelines for those who do not follow them: the impact of adherence assumptions on optimal screening guidelines.","volume":"26","author":"Pedersen","year":"2023","journal-title":"Value Health"},{"issue":"10","key":"zoi250670r36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.30350","article-title":"Lung cancer screening eligibility and screening patterns among Black and White adults in the United States.","volume":"4","author":"Lozier","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi250670r37","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.amepre.2022.06.022","article-title":"Patterns of birth cohort\u2013specific smoking histories by race and ethnicity in the U.S.","volume":"64","author":"Meza","year":"2023","journal-title":"Am J Prev Med"},{"issue":"9","key":"zoi250670r38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/thoraxjnl-2016-209892","article-title":"Risk stratification based on screening history: the NELSON lung cancer screening study.","volume":"72","author":"Yousaf-Khan","year":"2017","journal-title":"Thorax"},{"issue":"23","key":"zoi250670r39","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1002\/cncr.33835","article-title":"A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings.","volume":"127","author":"Toumazis","year":"2021","journal-title":"Cancer"},{"issue":"11","key":"zoi250670r40","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1016\/j.jtho.2023.09.352","article-title":"P1.14-04 European Lung Cancer Screening Implementation: 4-IN-THE-LUNG-RUN trial.","volume":"18","author":"van der Aalst","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"8","key":"zoi250670r41","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1056\/NEJMoa1211776","article-title":"Selection criteria for lung-cancer screening.","volume":"368","author":"Tammem\u00e4gi","year":"2013","journal-title":"N Engl J Med"},{"key":"zoi250670r13","unstructured":"Cancer Screening Committee recommendation on low-dose CT screening for lung cancer. November 15, 2022. Accessed January 6, 2023. https:\/\/cancerscreeningcommittee.ch\/en\/topics\/lung-cancer-screening-using-ldct\/"},{"key":"zoi250670r33","unstructured":"World Bank Group. Consumer Price Index (2010=100)\u2014United States. International financial statistics and data files. 2023. Accessed October 10, 2024. https:\/\/data.worldbank.org\/indicator\/FP.CPI.TOTL?locations=US"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2836784\/de_nijs_2025_oi_250670_1752614669.77508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:31:11Z","timestamp":1753371071000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2836784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.23044","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}